ISC

International Stem Cell Corporation (ISCO) is a clinical-stage biotechnology company focused on developing therapeutic and biomedical products using its proprietary human parthenogenetic stem cell (hpSC) technology. The company's platform creates pluripotent stem cells from unfertilized human eggs, addressing ethical concerns and potential immune rejection issues associated with traditional embryonic stem cells. Its lead program, ISC-hpNSC, is a neural stem cell therapy that has completed a Phase 1 clinical trial for the treatment of Parkinson's disease. Beyond neurology, ISCO is exploring applications in liver disease, retinal disorders, and traumatic brain injury. The company also operates subsidiaries that provide research-grade cells and stem cell-based skincare products.